Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2017 Earnings Results

Madrigal Pharmaceuticals Misses on EPS, Stock Down 0.70%

Madrigal Pharmaceuticals reported a loss of $0.69 per share for Q2 2017, with no revenue figures disclosed. The stock reacted negatively, dropping 0.70%, likely due to the lack of guidance and clarity on future performance. Investors may be concerned about the company's ability to navigate its clinical trials without clear financial expectations.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.69	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious outlook, emphasizing the importance of ongoing clinical trials. They did not provide specific guidance for future performance.

Management did not provide specific revenue guidance for the upcoming quarters.

The focus remains on advancing clinical trials and product development.

Madrigal Pharmaceuticals Misses on EPS, Stock Down 0.70%

Key numbers

Management commentary

Madrigal Pharmaceuticals, Inc.

More earnings this week

Madrigal Pharmaceuticals Misses on EPS, Stock Down 0.70%

Key numbers

Management commentary